• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    BioSig Enters into an LOI to Merge with Streamex Exchange Corp. Creating a Publicly Listed Real-World Asset Tokenization Company Led by Seasoned Industry Executives

    5/5/25 8:30:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $BSGM alert in real time by email

    Los Angeles, CA, May 05, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company is pleased to announce it has entered into a Letter of Intent ("LOI") to enter into a proposed merger or other business combination (the "Merger"), with Streamex Exchange Corporation ("Streamex") in an all-stock transaction, to bring a real-world asset tokenization company public on the Nasdaq.

    Proposed Transaction Highlights include:

    • Technology Stack – A fully developed and operational primary issuance and decentralized exchange infrastructure for on chain commodity markets. 
      • Commodity-focused real-world asset tokenization infrastructure and financing platform.
      • Tokenization and financing infrastructure for streamlining the investment process, increasing capital availability for companies and opportunities for investors. 
      • Gain access to real-world assets with the ease and security of crypto. Diversify  portfolios with tangible investments in a digital-first world.



    Figure 1: The Streamex Ecosystem



    Figure 2: The Streamex Platform

    About Streamex Exchange Corporation

    Streamex is a real-world asset (RWA) tokenization company focused in the commodities space. With the goal to bring commodity markets on chain, Streamex has developed primary issuance and exchange infrastructure that will revolutionize commodity finance. Streamex is led by a group of highly successful and seasoned executives from financial, commodities and blockchain industries.

    Streamex believes the future of finance lies in tokenization, innovative investment strategies, and decentralized markets. By merging advanced financial technologies with blockchain transparency, Streamex has created infrastructure and solutions that enhance liquidity, accessibility, and efficiency. Streamex's goal is to bridge the gap between traditional finance and the digital economy, unlocking new opportunities for investors and institutions worldwide.

    Co-Founders Henry McPhie and Morgan Lekstrom commented, "This is the next evolution of commodity and traditional finance; we are excited to bring to you a product that we believe can transform this legacy industry. In partnership with BioSig Technologies, we are working toward a definitive agreement to list Streamex on the Nasdaq. The world is rapidly moving towards digital and blockchain based financial markets. Billions in assets have already been tokenized and brought on chain by large financial institutions such as BlackRock, Goldman Sachs and HSBC. We at Streamex are excited to be first movers to bring the $2.1 Trillion mining and $142 Trillion global commodities market on chain though a streamlined and efficient platform powered by Solana."

    BioSig's CEO, Anthony Amato added, "This merger represents a transformative opportunity for both our company and our shareholders. By joining forces with Streamex, we are unlocking significant growth potential while continuing to advance our existing business. This partnership will expand our market reach, enhance our capabilities, and create even greater opportunities for driving substantial returns. I am incredibly excited about the promising future ahead for our shareholders."

    Board and Management Changes Post Closing of the Proposed Transaction

    • Appointment of a new Chief Executive Officer - Mr. Henry McPhie, Co-Founder and CEO of Streamex will lead the Company as Chief Executive Officer and member of the board of directors (the "Board") through its next phase of growth.

    • Appointment of a new Chairman - Mr. Morgan Lekstrom, Co-Founder and Chairman of Streamex will also join as Chairman of the Board.  
      • Founder of NexGold Mining Corp. (NEXG-TSX)
      • CEO & Director of Premium Resources, which just recapitalized $67.8M (PREM-TSX)

    • Current BioSig CEO and Chairman, Anthony Amato will remain on the Board.
    • Additional Board members to be added post definitive agreement signing.                                                   

    Strategic Advisor Additions Post Closing of the Proposed Transaction

      • Mr. Frank Giustra has agreed to join as a Strategic Investor and Advisor on Commodities. 
        • Founder of LionsGate Films (LGF-NYSE, $2B)
        • Founder of Wheaton Precious Metals, (WPM-NYSE, $37B)
        • Founder of GoldCorp, acquired by Newmont (NEM, $57B)
      • Mr. Mathew August has agreed to join as a Strategic Advisor on US Capital Markets.
        • Executive Chairman of Atlas Capital Partners a New York, NY based single family office investment firm and merchant bank
        • Active Venture Capitalist with significant investments within the Defense Tech, FinTech, Aerospace and other diversified industries
      • Mr. Mitchell Williams has agreed to join as a Strategic Advisor on US Capital Markets.
        • Managing Partner of a Private Investment Firm
        • Former Senior Managing Director, Head of Public Markets at Wafra Inc.
        • Former Sole Portfolio Manager of $4+ Billion at Oppenheimer Funds

    Proposed Terms of Merger

    By signing the Letter of Intent, this potential transaction marks a distinct shift in a positive direction for existing BioSig shareholders.

    • Immediately after the Merger, the current stockholders of Streamex will own approximately 19.9% of the outstanding Common Stock of the Company and a number of Series X Convertible Preferred Stock, par value $0.0001 per share ("Series X"), such that after taking into account the conversion of the Series X, the former stockholders of Streamex will own approximately 75% of the outstanding Common Stock of the Company, with the Company's current stakeholders owning the remaining equity of the Company.



    Forward-Looking Statements 

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause BioSig's actual results to differ from those contained in forward-looking statements, see BioSig's filings with the Securities and Exchange Commission, including the section titled "Risk Factors" in BioSig's Annual Report on Form 10-K, filed with the SEC on April 15, 2025. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise, except as required by law.



    Todd Adler
    BioSig Technologies, Inc.
    Investor Relations
    12424 Wilshire Blvd Ste 745
    Los Angeles, CA 90025
    [email protected]
    203–409–5444, x104
    
    Anthony Amato
    Chief Executive Officer
    [email protected]
    
    Henry McPhie 
    Co-Founder & CEO of Streamex 
    [email protected]
    https://www.streamex.com/
    https://x.com/streamex

    Primary Logo

    Get the next $BSGM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BSGM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BSGM
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by BioSig Technologies Inc.

    SCHEDULE 13G/A - Streamex Corp. (0001530766) (Subject)

    9/15/25 8:12:26 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form DEFA14A filed by BioSig Technologies Inc.

    DEFA14A - BioSig Technologies, Inc. (0001530766) (Filer)

    9/11/25 4:27:51 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig Technologies Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BioSig Technologies, Inc. (0001530766) (Filer)

    9/11/25 4:05:58 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BSGM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Giustra Frank bought $734,725 worth of shares (178,205 units at $4.12) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    9/15/25 8:19:20 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BSGM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Streamex Corp., NASDAQ: STEX & Simplify Asset Management $10 billion USD AUM ETF Manager Announces Letter of Intent Pursuing a Strategic Partnership to Drive ETF Innovation through Integration of Tokenized Gold Yield Assets and Tokenization of Existing ETFs

    Key Partnership Highlights: Streamex & Simplify have entered into a letter of intent outlining a framework for pursuing a strategic partnership to leverage each other's platforms for next-generation financial products.Focus on the integration of Streamex's tokenized yield-bearing gold into ETF structures, bridging blockchain innovation with institutional-grade financial products.Distribution expansion across both partners' platforms, subject to definitive agreements and regulatory approval.Jointly intending to collaborate, subject to definitive agreements, on developing ETP/ETF offerings designed to expand investor access to regulated, liquid, and yield-generating gold and commodity-backed

    9/17/25 8:30:00 AM ET
    $BSGM
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig Technologies, Inc. Announces Corporate Rebrand to Streamex Corp.

    LOS ANGELES & VANCOUVER, British Columbia, Sept. 10, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig"), which recently merged with Streamex Exchange Corporation ("Streamex") (together, "BSGM" or the "Company"), announced today that it will change its name to Streamex Corp., effective at 12:01 am Eastern Time on Friday, September 12, 2025. In connection with the name change, the Company will change its trading symbol to "STEX." The Company's common stock will commence trading on the Nasdaq Capital Market exchange under the new name and trading symbol on September 12, 2025. As of September 12, 2025, all Company stock trading, filings, and market related information

    9/10/25 11:54:24 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Monetary Metals Enters into Exclusive Partnership with Streamex (Nasdaq: BSGM) to Create Tokenized Yield-Bearing Gold Products

    Monetary Metals has signed an agreement with Streamex to provide yield on physical gold bullion with upwards of $1 billion USD in near term lease capacity SCOTTSDALE, Ariz. and LOS ANGELES, Sept. 9, 2025 /PRNewswire/ -- Monetary Metals, the pioneer in gold-and-silver-denominated fixed income products, has partnered with Streamex Exchange Corporation ("Streamex"), which recently merged with BioSig Technologies Inc. (NASDAQ:BSGM). Through this collaboration, Monetary Metals will gain exclusive rights to put Streamex's tokenized gold to work earning yield. The partnership adds an important new channel to bring gold to the Monetary Metals Gold Yield Marketplace® with a well-capitalized Nasdaq l

    9/9/25 8:00:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BSGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Giustra Frank bought $734,725 worth of shares (178,205 units at $4.12) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    9/15/25 8:19:20 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Giustra Frank

    3 - Streamex Corp. (0001530766) (Issuer)

    9/15/25 8:16:15 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    New insider Williams Mitchell Young claimed ownership of 1,000,000 units of Restricted Common Stock (SEC Form 3)

    3 - BioSig Technologies, Inc. (0001530766) (Issuer)

    6/9/25 6:31:07 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BSGM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on BioSig Technologies with a new price target

    The Benchmark Company initiated coverage of BioSig Technologies with a rating of Buy and set a new price target of $42.00

    2/8/21 7:32:50 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BSGM
    Leadership Updates

    Live Leadership Updates

    View All

    BioSig & Streamex Appoint Defi Expert and Visionary, Russell Starr as Strategic Advisor

    BioSig Technologies, Inc. ("BioSig" or the "Company"), which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ:BSGM), is pleased to announce the appointment of Russell Starr as Strategic Advisor to Streamex. Mr. Starr brings decades of experience in capital markets, business development, and transformative deal-making across, defi, traditional finance and emerging sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711280588/en/ A former executive on Bay Street and respected entrepreneur and financier, Mr. Starr has built a reputation for navigating high-stakes financial transactions and guiding comp

    7/11/25 9:00:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig & Streamex Appoint Parcl Co-Founders Trevor Bacon and Kellan Grenier as Strategic Advisors

    Los Angeles, CA & Vancouver, BC, June 09, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig"), which acquired Streamex Exchange Corporation as its wholly owned subsidiary ("Streamex") in May 2025, is pleased to announce the appointment of Trevor Bacon and Kellan Grenier, co-founders of Parcl, as Strategic Advisors. Together, they bring deep expertise at the intersection of decentralized finance, synthetic asset creation, and real-world asset tokenization. Parcl is a leading blockchain-native platform that enables users to gain exposure to real estate markets through synthetic, perpetual trading. Built on Solana, the platform offers users the ability to speculate on

    6/9/25 10:30:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig & Streamex Appoint Co-Founder of the Osisko Group & Mining Visionary, Sean Roosen as Strategic Advisor

    Los Angeles, CA and Vancouver, BC, June 04, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig"), which acquired Streamex Exchange Corporation as its wholly owned subsidiary ("Streamex") in May 2025, is pleased to announce the appointment of Sean Roosen as Strategic Advisor to Streamex. Mr. Roosen, a globally recognized mining entrepreneur and financier, brings over three decades of experience in building and scaling multibillion-dollar resource ventures. Mr. Roosen is the Founder, Executive Chairman, and Chief Executive Officer of Osisko Development Corp., a premier North American gold development company. He is also the founder and former Executive Chairman and CE

    6/4/25 8:25:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BSGM
    Financials

    Live finance-specific insights

    View All

    BioSig Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module

    Westport, CT, Sept. 22, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the release of PURE EP™ Software Version 6 with ACCUVIZ™ Module. Built around three highly differentiating features, PURE EP™ Software Version 6 with ACCUVIZ™ Module introduces the proprietary High Frequency Algorithm (HFA), a novel feature that identifies the key frequency components of cardiac data that can be difficult to identify within the traditional waveform presentation. O

    9/22/22 9:00:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig to Host Conference Call on December 21, 2021

    Westport, CT, Dec. 13, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would host a conference call on Tuesday, December 21, 2021, at 2 PM ET. Conference Call DetailsDate: Tuesday, December 21, 2021Time: 2:00 PM Eastern Time (ET)Dial-in number for US callers (toll-free): 877-407-8293Dial-in number for U.S. and international callers (toll): +1 201-689-8349 To join the conference call online, please click here: BioSig Webcast A

    12/13/21 8:30:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BSGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BioSig Technologies Inc.

    SC 13G/A - BioSig Technologies, Inc. (0001530766) (Subject)

    11/14/24 3:58:00 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by BioSig Technologies Inc.

    SC 13G - BioSig Technologies, Inc. (0001530766) (Subject)

    2/14/24 3:31:45 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by BioSig Technologies, Inc. (Amendment)

    SC 13G/A - BioSig Technologies, Inc. (0001530766) (Subject)

    7/12/21 8:29:21 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care